ClinicalTrials.gg
CompletedNCT00159718DUAALUpdated Jan 28, 2021

Double Blind Atorvastatin Amlodipine Study

A Phase 4 interventional study of amlodipine and atorvastatin in Angina, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in 11 countries. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

To evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia.

Amlodipine's use in angina has been well documented in clinical trials such as the Circadian Anti-Ischemia Program in Europe (CAPE), but the impact on vascular inflammation in clinical practice has not been tested. Furthermore, the potentially synergistic benefit of atorvastatin and amlodipine on inflammation ischemic activity has not been studied.

02

Conditions studied

  • Angina

Browse trials for

03

In context

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.

This study's enrollment of 360 is above the median of 100 across 273 interventional studies indexed under Angina Pectoris.

Browse Angina Pectoris studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Holter monitoring at baseline which demonstrates a total of 15 minutes of ischemia and/or 3 ischemic events per 48 hours.
  • Total cholesterol > 5.2 mmol/L (200 mg/dL) on diet alone.

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction within 2 months prior to the study.
  • Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
360 participants

Interventions

06

What researchers measure

Primary outcomes

  1. From the 48 hour holter monitoring the number of ischemic episodes will be assessed at baseline (week 1), week 18 and at the final visit (week 26).

Secondary outcomes

  1. Inflammatory markers will be assessed at baseline (week 2), week 6, week 18 and

  2. week 26. Inflammatory markers to be analyzed are the following: C-reactive

  3. protein, amyloid A and interleukin 6.

  4. From the exercise tolerance tests the time to onset of 1 mm ST depression, time to

  5. onset of angina and total exercise time will be assessed at baseline (week 2),

  6. week 18 and week 26.

07

Study locations

33 sites
  • Pfizer Investigational Site
    Rijeka, Croatia
  • Pfizer Investigational Site
    Zagreb, Croatia
  • Pfizer Investigational Site
    Ostrava - Kuncice, Czechia
  • Pfizer Investigational Site
    Plzen, Czechia
  • Pfizer Investigational Site
    Praha, Czechia
  • Pfizer Investigational Site
    Pribram, Czechia
  • Pfizer Investigational Site
    Rokycany, Czechia
  • Pfizer Investigational Site
    Tallinn, Estonia
  • Pfizer Investigational Site
    Tartu, Estonia
  • Pfizer Investigational Site
    Debrecen, Budapest, Hungary
  • Pfizer Investigational Site
    Balatonfured, Hungary
  • Pfizer Investigational Site
    Berettyoujfalu, Hungary
  • Pfizer Investigational Site
    Budapest, Hungary
  • Pfizer Investigational Site
    Zalaegerszeg, Hungary
  • Pfizer Investigational Site
    Daugavpils, Latvia
  • Pfizer Investigational Site
    Riga, Latvia
  • Pfizer Investigational Site
    Valmiera, Latvia
  • Pfizer Investigational Site
    Baerum Postterminal, Norway
  • Pfizer Investigational Site
    Oslo, Norway
  • Pfizer Investigational Site
    Bytom, Poland
  • Pfizer Investigational Site
    Katowice, Poland
  • Pfizer Investigational Site
    Poznan, Poland
  • Pfizer Investigational Site
    Warszawa, Poland
  • Pfizer Investigational Site
    Brasov, Jud. Brasov, Romania
  • Pfizer Investigational Site
    Bucharest, Romania
  • Pfizer Investigational Site
    Craiova, Romania
  • Pfizer Investigational Site
    Bratislava, Slovakia
  • Pfizer Investigational Site
    Observatory, Cape, South Africa
  • Pfizer Investigational Site
    Parow, Cape, South Africa
  • Pfizer Investigational Site
    Capa, Istanbul, Turkey
  • Pfizer Investigational Site
    Bornova/izmir, Turkey
  • Pfizer Investigational Site
    Samsun, Turkey
  • Pfizer Investigational Site
08

References and documents

Publications

  • Deanfield JE, Sellier P, Thaulow E, Bultas J, Yunis C, Shi H, Buch J, Beckerman B. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J. 2010 Nov;31(21):2650-9. doi: 10.1093/eurheartj/ehq133. Epub 2010 May 21. PubMed 20494902 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2001 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jul 2001
Completion
Jan 2007
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00159718
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jul 2001
Completion
Jan 2007
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Atorvastatin

Start the discussion